tbuckley/cabot-search huggingface dataset:
Memoires de l'Academie de Chirurgie, Paris
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Factores Prognostic in Psychotherapia
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The future of health care: military model? Canadian cost cutting
Authors: R. E. Miller
Journal: JAMA (1990)

<h3>To the Editor.—</h3> Dr Bronow<sup>1</sup>and the National Organization of Physicians Who Care are properly concerned about the looming changes in physician payment and practice patterns. Many of their fears, though, may not be wholly justified. We need not go as far as Saskatchewan to find an example of a universal-enrollment, managed care system that has served physicians and patients admirably well. The US military medical system provides comprehensive, cradle-to-grave medical care, with no out-of-pocket cost to the patient, to over 9 million people. At a cost of about $1444 per beneficiary,<sup>2</sup>the system is also more cost-efficient by 28% than the US per capita health care cost and is nearly as cost-efficient as the Canadian and German systems.<sup>3</sup>Poor, elderly, and chronically ill patients are all cared for. While staffing fluctuations occasionally lead to temporary curtailment of services in military hospitals, the Department of Defence—sponsored insurance
Genetics
Authors: Raymond L. Teplitz
Journal: JAMA (1982)

Diagnosis of genetic diseases has become more readily available and precise since the 1960s. Reproducible methods for growing cells, even from a blood sample, and preparation of chromosomes permitting easy karyotyping brought cytogenetics within the access of most clinicians. Development of electrophoretic techniques capable of resolving structural and enzymatic proteins and detecting their variations increased the diagnostic power of genetics from the gross chromosomal level to the single-gene level. Until now, it was the protein coded by the relevant gene that was analyzed, rather than the gene itself. Thus, the molecule of hemoglobin S is identified in sickle cell disease and not the gene. In Tay-Sachs disease, N-acetylhexosaminidases A and B are ascertained, their absence resulting in blocking of the metabolism of sphingolipids. Absence or variation of the protein is interpreted as absence or modification (mutation) of the gene coding for the protein. <h3>Restriction Enzyme Gene Analysis</h3> Now, the possibilities
The Urethra and the Urethroscope. A Manual of Practical Urethroscopy.
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 9911: Hypoxia-inducible Factor-1α Knockout in Myeloid Lineage exaggerates Angiotensin II-induced Abdominal Aortic Aneurysm
Authors: Yusuke Takahara, Tomotake Tokunou, Hiroshi Kojima, Toshihiro Ichiki, Yoshitaka Hirooka, Kenji Sunagawa
Journal: Circulation (2015)

Background: Hypoxia-inducible factor-1α (Hif1α) is a transcriptional factor that regulates various genes reacting hypoxic conditions. In atherosclerotic legion, Hif1α is thought to be regulating inflammatory responses. We previously reported that myeloid specific Proryl hydroxylase domain protein2 deletion had protective effect on cardiovascular disease in animal model. The roll of Hif1α of myeloid lineage in inflammatory response is not determined. Methods and Results: Myeloid specific Hif1α knock out mice (MyHif KO) were created using Cre-lox recombination. MyHif KO mice were crossed with Apolipoprotein E knockout (ApoEKO) mice to create double knock out mice (MyHif/ApoE DKO group, n=18). ApoEKO with Hif1α flox/flox (without Cre recombinase) mice were used as control group (n=11). Two groups were fed with high fat diet (HFD) and infused with Angiotensin II (AII, 1800ng/kg/min) by osmotic mini pump for 4 weeks to promote abdominal aortic aneurysm (AAA) formation. The genotype of mice was blinded during experiment. There was no significant difference in survival rate between two groups. MyHif/ApoE DKO increased AAA formation rate (94.4% vs 81.8% in control) and aortic diameter (2.42mm±0.21mm vs 1.89±0.27mm in control). AAA classification reported by Daugherty et al was significantly exaggerated in MyHif/ApoE DKO group (2.75±0.35 vs 1.63±0.46 in control, P=0.03). Elastin degradation grade was checked by Elastica van Gieson staining. MyHif/ApoE DKO also deteriorated the elastin degradation grade (3.91±0.08 vs 3.25±0.31, P=0.01). The number of macrophages which migrated to abdominal aorta was increased in MyHif/ApoE DKO group (565±110.3/section vs 260.5±136.5/section in control, P=0.0507), whereas MyHif/ApoE DKO did not change the glucose level, blood pressure and body weight. Peritoneal macrophages from MyHif/ApoE DKO were significantly activated the migration induced by monocyte chemotactic protein-1 in dose dependent manner. Conclusion: Hif1α of myeloid lineage might have vascular protective effect via suppressing the macrophage activation in the model of AII-induced AAA in mice.
Cardiovascular disease
Authors: J. M. Gore
Journal: JAMA (1994)

No one can dispute that thrombolytic therapy saves lives. However, the question remains, which is the most cost-effective agent: streptokinase (SK) or tissue-type plasminogen activator (t-PA)? Several studies have suggested that t-PA is more effective than SK; however, given the fact that t-PA is nearly 10 times as expensive as SK, further clinical trials were performed to verify that t-PA is more effective. The results of the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) study, which were reported in the fall of 1993,<sup>1,2</sup>strongly suggest that t-PA is more effective than SK. The GUSTO study enrolled 41 021 patients from 1081 hospitals in 15 countries and compared the following four treatment strategies for acute myocardial infarction (AMI): (1) SK plus subcutaneous heparin; (2) SK plus intravenous (IV) heparin; (3) combined t-PA, SK, and IV heparin; and (4) accelerated t-PA (administration of t-PA over
Prazosin in the diagnosis and treatment of pheochromocytoma
Authors: J. M. Wallace
Journal: JAMA (1978)

In a patient with paraganglioma, severe hypertension due to high levels of plasma norepinephrine was easily controlled with prazosin hydrochloride, 6 to 8 mg/day for 19 days before surgery. A prolonged antihypertensive response to the first two 1-mg doses suggested the presence of pheochromocytoma. This experience dramatizes the remarkable effectiveness of prazosin as a postsynaptic α-adrenergic receptor blocker and invites further trials of the drug for both the diagnosis and treatment of pheochromocytoma. (<i>JAMA</i>240:2752-2753, 1978)
LETTER FROM LONDON.
Authors: None G. O. M.
Journal: JAMA (1891)

<h3>LETTER FROM LONDON.</h3> (FROM OUR OWN CORRESPONDENT.) Sulphichthyolic Acid and its Preparations in the Treatment of Inflammatory Diseases of Women—The Leprosy Commission in India—Spasmodic Dysmenorrhcea—Disinfection af Infected Premises—Miscellaneous Gleanings. When ichthyol was first introduced into therapy it made a very considerable reputation, and was found by experiment to have a contractile influence upon the vascular system so that hyperaemia, inflammation and pain in any situation were relieved by its application. The disorders caused by or associated with dilation of the vascular system or anomalies of the circulation being so numerous, the remedy ran some risk of being regarded as put forward as a panacea. This was even more the case when the substance began to be used internally against organic affections or disordered functions, which could be regarded as due to or intimately connected with a dilated vascular condition. Quite a new direction for the display of the peculiar properties
T-DM1 Combo Graduates from I-SPY 2
Journal: Cancer Discovery (2016)

The combination of the antibody-drug conjugate ado-trastuzumab emtansine, or T-DM1, plus pertuzumab given prior to surgery outperformed standard therapy in women with HER2-positive breast cancer enrolled in the I-SPY 2 trial. The results, reported at the American Association for Cancer Research Annual Meeting 2016, suggest that the drug combination would be successful in a phase III trial, potentially leading to an effective, less toxic treatment option for women at risk for metastatic disease.
Maternal age and newborn blood pressure
Authors: Matthew W Gillman, Carol L Link, Janet W Rich-Edwards, Ellice S Lieberman, Steven E Lipshultz
Journal: Circulation (2001)

0018 Background. Blood pressure (bp) level after birth may reflect the fetal cardiovascular environment, but few data exist on newborn bp. Methods. We report findings from a new cohort of pregnant women and their offspring, Project Viva. Enrollment as of September, 2000, is 1338 pregnant women (of a target 6000), and 581 have delivered. Data collected include maternal dietary, sociodemographic, economic, psychological, lifestyle, and clinical variables; and infant bp, pulse rate, length, weight, and circumferences measured during the first 2 days of life. We averaged 5 systolic bp readings taken with a Dinamap automated bp recorder. This abstract is limited to the first 260 measured newborns (131 girls and 129 boys) and partial maternal data. Results. The highest newborn systolic bp was in children of the oldest mothers, and the lowest in the maternal age group 20-24 years ( Table). Multivariate adjustment for infant birth weight and sex and for maternal body mass index, pregnancy weight gain, 3 rd trimester bp, and number of pregnancies did not attenuate the differences. For example, adjusted mean newborn systolic bp was 10.8 (95% CI 2.4, 19.2) mmHg higher among children of 40-44 y.o. than 20-24 y.o. mothers. Variables minimally or not related to newborn systolic bp included birth weight and length, pulse rate, head, chest, and abdominal circumferences, gestational age, and maternal body mass index, weight gain, and systolic bp. Conclusions. Higher maternal age was associated with higher newborn systolic bp. Whereas bp later in childhood predicts adult hypertension and its consequences, newborn bp may represent different phenomena, such as pre- and peri-natal influences on cardiac structure and function. Studies of newborn bp may shed new light on effects of the fetal environment on lifelong cardiovascular health. Table 1.
Doctors Charged with Manslaughter in the Course of Medical Practice, 1795–2005: A Literature Review
Authors: R E Ferner, Sarah E McDowell
Journal: Journal of the Royal Society of Medicine (2006)

Objectives To quantify the number of doctors charged with manslaughter in the course of legitimate medical practice and to classify cases, as mistakes, slips (or lapses), and violations, using a recognized classification of human error system. Design We searched newspaper databases, Medline, Embase, and the Wellcome library catalogue to identify relevant cases from 1795 to December 2005. Setting Medical practice in the United Kingdom. Main Outcome Measure Number of doctors charged with manslaughter in the course of medical practice. Results We identified 85 doctors charged with manslaughter since 1795. The number of doctors charged was relatively high in the mid-19th century and the inter-war years, and has dramatically increased since 1990. Sixty of the doctors were acquitted, 22 were convicted, and three pleaded guilty. Most doctors were charged as a consequence of mistakes (37) or slips (17), and a minority because of alleged violations (16). Conclusions The number of doctors prosecuted for manslaughter has risen steeply since 1990, but the proportion of doctors convicted remains low. Prosecution for deliberately violating rules is understandable, but accounts for only a minority of these cases. Unconscious errors–-mistakes and slips (or lapses)–-are an inescapable consequence of human actions and prosecution of individuals is unlikely to improve patient safety. That requires improvement to the complex systems of health care.
THE GENERAL PRACTITIONER AND THE TECHNIQUE OF PATHOLOGIC EXAMINATION.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A new minor tranquilizer. Oxazepam (Serax)
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical Research and the Golden Rule
Journal: JAMA (2018)

Recent phenomenal innovations and discoveries in medical science have prompted reexamination of ethical standards in experimentation.In the ensuing discussions and controversies, medical ethics has been defined in moral, legal, sociologic, theologic, and many other terms, and its limitations, flexibility, and function have been widely articulated and debated.But the essence of medical ethics, the golden rule, has been largely overlooked or undervalued: "Whatsoever ye would that men should do to you, do ye even so to them" (Matthew 7:12).If man lived alone, a code of ethics would be superfluous; only in society does it become requisite and intelligible.Society, in fact, regulates human ethics.The canon of ethics of all communal living-regarding material possessions, etiquette, family or international relations, and other forms of social behavioremanated from the golden rule.In medical science, the myriad considerations that affect the behavior of the physician toward his patient require some elaboration of the golden rule.But the crux of the doctor-patient relation, about which so many words have issued forth recently, reposes in this precept.For centuries the Hippocratic oath served as the code of medical ethics, embraced voluntarily by physicians when they embarked on a medical career.Evolutionary changes in medical practice and research have necessitated certain revisions in medical ethics, in the form of the Ethical Guidelines for Clinical Investigation established by the American Medical Association House of Delegates, the Nuremberg Code, the 1964 Declaration of Helsinki adopted by the World Medical Association, the formulation of the British Medical Research Council of 1964, the United States Public Health Service rules and regulations governing experimentation and research, and others.These codes evolved because of the difficulty and the weighty responsibility of unprecedented medical decisions, but they all represent general guides, not categorical imperatives, and the physician-scientist's self-discipline, judgment, and conscience must ultimately operate in individual decisions.Tyrannical restraints on experimentation would certainly have precluded the invaluable contributions of Vesalius, Harvey, Jenner, Walter Reed, and countless other eminent scientists.Rigid proscriptions about human experimentation would also
Sorafenib in combination with local microtherapy guided by gadolinium-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma (SORAMIC).
Authors: Jens Ricke, Kerstin Schuette, Olivier Rosmorduc, Markus Peck-Radosavljevic, Chris Verslype, Bruno Sangro, Jerzy Walecki, Heinz-Josef Klumpen, Bora Peynircioglu, Suayib Yalcin, Carlo Bartolozzi, Holger Amthauer, Peter Malfertheiner
Journal: Journal of Clinical Oncology (2014)

TPS4154 Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality with an increasing incidence. For the individual patient tumor stage , liver function and general health status are the principal prognostic factors. The clinical management of HCC requires a comprehensive, multidisciplinary approach. In early HCC curative treatment can be achieved by local ablation, resection or liver transplantation. In intermediate stages patients with HCC are offered locoregional treatment with palliative intent. Yttrium-90-radioembolisation (SIRT)) is currently evaluated in this setting with promising results. In advanced disease systemic therapy with sorafenib is standard of care in patients with preserved liver function. Studies on the combined use of locoregional and systemic therapy with their potential of a beneficial synergism are few and conducted in a small number of patients. The critical question is whether the combination is more benefit or more harm. Methods: This phase II-study is composed of three substudies with the following primary objectives: 1. In patients in whom local ablation is appropriate to determine if sorafenib in combination with RFA prolongs the time-to-recurrence in comparison with RFA plus placebo. Primary endpoint: time to recurrence, n = 290 patients 2. In patients in whom RFA is not appropriate (palliative treatment group) to determine if the combination of SIRT and sorafenib improves the overall survival in comparison to sorafenib alone. Primary endpoint: overall survival, n = 375 patients 3. To confirm in a 2-step procedure that Gd-EOB-DTPA enhanced MRI is non-inferior or superior compared with contrast-enhanced multislice CT for stratification of patients to a palliative or a local ablation treatment strategy. Primary endpoint: correct stratification of patients to a palliative versus local ablation treatment strategy; n = 830 patients The trial has started in December 2010 as a multinational and multicentric study. 349 patients have been enrolled until January 31st 2014 with 200 patients randomized in the palliative arm and 57 patients treated in the curative arm. Clinical trial information: 01126645.